- Elanco Animal Health, headquartered in Greenfield, Indiana, specializes in animal health pharmaceuticals, focusing on innovative solutions for both livestock and companion animals, and reported a revenue of $4,715 million in 2025 with a 6% increase year-over-year.
- In 2025, Elanco exceeded its innovation revenue target with $892 million, launched several blockbuster products including Credelio Quattro, and raised its 2026 innovation revenue target to $1.15 billion.
- Key products like Credelio Quattro have reached blockbuster status, achieving over $100 million in net sales within eight months, highlighting Elanco's strong position in the pet health market.
- Elanco's ideal buyers include veterinarians and pet owners seeking advanced health solutions, particularly those addressing parasite control, making it crucial for sales teams to engage with this market as demand for innovative animal health products continues to grow.
Elanco Animal Health operates with a diverse departmental structure, comprising eight distinct areas. The largest departments are Sales and Information Technology, each with a headcount of four, indicating a strong emphasis on both market engagement and technological support. Other departments, such as Engineering, Executive, and Operations, maintain a balanced presence with two employees each, reflecting a strategic focus on core operational functions. This mix suggests a well-rounded organizational approach to both customer-facing and internal support roles.
The company has a geographically diverse workforce with seven locations across the United States. Key locations include Greenfield, IN, and Indianapolis, IN, each contributing one employee, while a significant portion of the workforce is categorized under 'Other' locations, indicating a distributed operational model. This distribution highlights Elanco's ability to maintain a presence in multiple regions, ensuring flexibility and responsiveness to various market needs.
